Clinical Trials Logo

Solid Tumor, Unspecified, Adult clinical trials

View clinical trials related to Solid Tumor, Unspecified, Adult.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04577963 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Start date: August 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2). The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase. - Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated) - Cohort B: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-Naïve) - Cohort C: Advanced or Metastatic Endometrial Cancer (EC) (IO-Naïve) - Cohort D: Advanced or Metastatic Colorectal Cancer (mCRC) (IO-Naïve)

NCT ID: NCT03628677 Active, not recruiting - Clinical trials for Solid Tumor, Unspecified, Adult

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Start date: September 12, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.